TOP TEN perturbations for 41150_r_at (Homo sapiens)

Organism: Homo sapiens
Gene: 41150_r_at
Selected probe(set): 212349_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 41150_r_at (212349_at) across 6672 perturbations tested by GENEVESTIGATOR:

lung adenocarcinoma study 9 (metastase; lymph node) / lung adenocarcinoma study 9 (metastase; brain)

Relative Expression (log2-ratio):-2.56633
Number of Samples:3 / 6
Experimental lung adenocarcinoma study 9 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary lung adenocarcinoma.
Control lung adenocarcinoma study 9 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary lung adenocarcinoma.

T-cell activation study 2 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):1.6455097
Number of Samples:2 / 2
Experimental T-cell activation study 2
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days..
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):1.6308689
Number of Samples:3 / 3
Experimental glioma study 17 (glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):1.4779453
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample

Relative Expression (log2-ratio):1.4181023
Number of Samples:2 / 2
Experimental T-cell activation study 3
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs.
Control resting CD4 T-lymphocyte (crude fraction) sample
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction.

ovarian tumor study 17 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):1.3957434
Number of Samples:9 / 10
Experimental ovarian tumor study 17
Human epithelial tumor cell samples from the ovary of patients with primary clear cell carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases.

colorectal cancer study 1 / normal colon tissue

Relative Expression (log2-ratio):1.3516083
Number of Samples:6 / 6
Experimental colorectal cancer study 1
Laser microdissected human colorectal cancer sample.
Control normal colon tissue
Laser microdissected human colonic epithelial cells sample.

glioma study 16 (astrocytoma) / normal brain tissue

Relative Expression (log2-ratio):1.3413467
Number of Samples:8 / 2
Experimental glioma study 16 (astrocytoma)
Primary astrocytoma tissues obtained from the operating room. Tumors were diagnosed and graded according to the current WHO classification (grade III-IV).
Control normal brain tissue
Normal brain tissue sample from healthy donors.

rectal cancer study 2 (post; chemoradiotherapy) / rectal cancer study 2 (post; no therapy)

Relative Expression (log2-ratio):-1.3296232
Number of Samples:4 / 2
Experimental rectal cancer study 2 (post; chemoradiotherapy)
Tumor tissue samples obtained from the rectum of patients with rectal adenocarcinoma during a surgical resection, after a treatment with neoadjuvant concurrent (5-FU-based) chemoradiotherapy (CRT). The regimen of the neoadjuvant CRT was as follows: folinic acid 20mg/m2, 5-flurouracil (5-FU), 350mg/m2 d1-5, and d29-33 with 45 Gy in 25 fractions. Samples were collected after 6-8 weeks of completing the therapy. Patients were selected for neoadjuvant CRT based upon clinical and MRI staging features. Radiotherapy was CT planned, using a 3 field technique (posterior and two lateral fields), multileaf collimation and with patients having a full bladder during the radiotherapy. Patients were proven to be medically fit for treatment (WHO PS 0-2), with no significant medical co-morbidities, in particular no history of unstable or severe ischemic heart disease, and adequate renal (creatinine clearance >50ml/min) and liver function (billirubin <1.5 ULN, transaminases and alkaline phosphatase <2x ULN ). The staging was performed by clinical examination high resolution MRI of the pelvis (under anaesthesia at the discretion of the treating surgeon), and CT scan of the thorax and abdomen. Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.
Control rectal cancer study 2 (post; no therapy)
Tumor tissue samples obtained during a surgical resection from the rectum of untreated (no pre-operative treated) patients with rectal adenocarcinoma.Tumor stage was assigned according to TMN classification of UICC 6th edition 2002.

glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):1.3240261
Number of Samples:2 / 4
Experimental glioma study 17 ( small cell glioblastoma; unsorted)
Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

Organism: Homo sapiens
Gene: 41150_r_at
Selected probe(set): 210433_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 41150_r_at (210433_at) across 6672 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 16 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):1.4962025
Number of Samples:3 / 5
Experimental ovarian tumor study 16
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

T-helper activation study 1 (340min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):1.413537
Number of Samples:2 / 2
Experimental T-helper activation study 1 (340min)
Alloantigen specific helper T-cells were stimulated for 340min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

T-helper activation study 1 (280min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):1.3026342
Number of Samples:2 / 2
Experimental T-helper activation study 1 (280min)
Alloantigen specific helper T-cells were stimulated for 280min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

T-helper activation study 1 (300min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):1.2606926
Number of Samples:2 / 2
Experimental T-helper activation study 1 (300min)
Alloantigen specific helper T-cells were stimulated for 300min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-1.2551947
Number of Samples:2 / 3
Experimental glioma study 17 (small cell glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

Hep-G2 / HepaRG

Relative Expression (log2-ratio):1.1673479
Number of Samples:9 / 12
Experimental Hep-G2
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):1.0423756
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

T-helper activation study 1 (260min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):1.0322008
Number of Samples:2 / 2
Experimental T-helper activation study 1 (260min)
Alloantigen specific helper T-cells were stimulated for 260min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-1.0165052
Number of Samples:3 / 3
Experimental glioma study 17 (glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

exercise study 33 (OUT; fast twitch; post-exerc.) / exercise study 33 (YT; fast twitch; post-exerc.)

Relative Expression (log2-ratio):0.9184675
Number of Samples:3 / 6
Experimental exercise study 33 (OUT; fast twitch; post-exerc.)
Fast twitch myosin heavy chain muscle fibers (MHC) IIa were obtained from vastus lateralis muscle. Biopsies were taken from old untrained (OUT) women (85±1 years) 4 hours after the first resistance exercise. Fibers were separated under the light microscope and MHC isoform was determinated based on SDS-PAGE analysis. Exclusion criteria: acute/chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin or non-insulin-dependent diabetes, abnormal blood, or urine chemistries, arthritis, a history of neuromuscular problems, tobacco smoking. Individuals, that had ever completed any formal exercise programs or physical activity outside of their activities of daily living, were excluded as well.
Control exercise study 33 (YT; fast twitch; post-exerc.)
Fast twitch myosin heavy chain muscle fibers (MHC) IIa were obtained from vastus lateralis muscle. Biopsies were taken from young trained (YT) women (23±2 years old) 4 hours after the 36th (last) exercise session. Participants underwent 12 weeks of progressive resistance training including 36 training sessions (3 days/week) with three sets of 10 bilateral knee extensions at 70–75% of their one-repetition maximum (1 RM). Fibers were separated under the light microscope and MHC isoform was determinated based on SDS-PAGE analysis. Exclusion criteria: acute/chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin or non-insulin-dependent diabetes, abnormal blood, or urine chemistries, arthritis, a history of neuromuscular problems, tobacco smoking. Individuals, that had ever completed any formal exercise programs or physical activity outside of their activities of daily living, were excluded as well.